Regeneron: Antibody Cocktail 100 Percent Effective Against Symptomatic COVID-19 Infections
Eli Lilly also reported positive results for neutralizing antibody treatment
The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, on Sept. 17, 2020. Brendan McDermid/Reuters
Regeneron Pharmaceuticals on Tuesday announced that a phase 3 trial still in progress of an antibody cocktail has shown a 100 percent prevention of symptomatic COVID-19 infections.
Interim results also show approximately 50 percent lower overall rates of infection across all patients.
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
